Venmax Drugs and Pharmaceuticals Ltd. Approves Amendment to Share Capital Clause in Amalgamation Scheme
Venmax Drugs and Pharmaceuticals Limited announced an amendment to the share capital clause (Para 2.2) within the draft scheme of amalgamation concerning Hatri Pharma Private Limited (Transferor Company). The decision was made during a Board of Directors meeting held on March 27, 2026.The Board Meeting commenced at 2:30 p.m. and concluded at 3:30 p.m.
The modified draft scheme of amalgamation, incorporating the changes to the share capital structure, is now attached.
Share Capital Details
The following table details the share capital information:
| Disclosure of Information | Disclosure of Information | Disclosure of Information | Disclosure of Information |
|---|---|---|---|
| Authorized Share Capital | Authorized Share Capital | Authorized Share Capital | Authorized Share Capital |
| 2,20,00,000 equity shares of Rs. 10/- each | Rs. 22,00,00,000 | 2,20,00,000 equity shares of Rs. 10/- each | Rs. 22,00,00,000 |
| Issued, Subscribed and Paid-up Share Capital | Issued, Subscribed and Paid-up Share Capital | Issued, Subscribed and Paid-up Share Capital | Issued, Subscribed and Paid-up Share Capital |
| 80,07,930 equity shares of Rs. 10/- each fully paid up | Rs. 8"00,79,300 | 1,15,82,930 equity shares of Rs. 10/- each fully paid up | Rs. 1,15,82,9300 |
| Convertible Equity Share Warrants Pending Allotment | Convertible Equity Share Warrants Pending Allotment | Convertible Equity Share Warrants Pending Allotment | Convertible Equity Share Warrants Pending Allotment |
| 72,56,400 equity share warrants of Rs. 5 each received | Rs.3,62,80,000 | 36,81,000 equity share warrants of Rs. 5 each received | Rs. 1,84,05,000 |
The Transferor Company has issued 1,00,25,000 convertible equity share warrants at a price of Rs. 20 per warrant. Of these, 63,44,000 equity shares have been allotted to warrant holders, with 36,81,000 equity shares warrant conversion still pending.
Hatri Pharma Private Limited is engaged in the manufacturing of drug intermediates, fine chemicals, and contract manufacturing. Venmax Drugs and Pharmaceuticals Limited engages in trading of nutraceuticals products and drug intermediates. The amalgamation is expected to improve operating margins for Venmax and revive the business of Hatri Pharma.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.